Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

• The magnitude of response observed in the active treatment cohort relative to the device-only control arm provides clinically meaningful evidence of drug-mediated therapeutic effect

  60% confidence

• SkinJect and Gorlin Syndrome collectively represent an approximately $2 billion market opportunity

  60% confidence

• 73% clinical clearance in the 200-µg arm suggests that approximately 3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention

  60% confidence

• The 200-µg treatment cohort demonstrated the strongest efficacy signal, achieving 73% clinical clearance and 40% histological clearance at Day 57

  60% confidence

• The Company believes the dataset represents decision-grade evidence supporting continued development of the SkinJect program and advancement toward regulatory discussions and potential strategic partnerships

  60% confidence

• The biological activity observed in the device-only arm likely reflects tumor disruption and localized immune activation resulting from microneedle insertion

  60% confidence

• Teverelix represents an approximately $6 billion market opportunity for cardiovascular high-risk advanced prostate cancer and acute urinary retention relapse

  60% confidence

• The study results demonstrate clear separation in clinical response between the D-MNA treatment arm (73%) and P-MNA treatment arm (38%) in the 200-µg cohort at Day 57

  60% confidence

• Basal cell carcinoma is the most common cancer worldwide

  60% confidence